Acquisition by Koski Robert C of 160000 shares of Oragenics at 1.2 subject to Rule 16b-3

Read at macroaxis.com

Published over six months ago View all stories for Oragenics | Oragenics Hype Analysis

Acquisition of 160000 non-employee director option (right to buy) at 1.2 of Oragenics by Koski Robert C on 2nd of November 2024. This event was filed by Oragenics with SEC on 2021-02-18. Statement of changes in beneficial ownership - SEC Form 4

We analyze Oragenics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Oragenics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Oragenics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Oragenics stock to make a market-neutral strategy. Peer analysis of Oragenics could also be used in its relative valuation, which is a method of valuing Oragenics by comparing valuation metrics with similar companies.

Check out Oragenics Hype Analysis, Oragenics Correlation and Oragenics Performance. To learn how to invest in Oragenics Stock, please use our How to Invest in Oragenics guide.You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oragenics. If investors know Oragenics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oragenics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Oragenics is measured differently than its book value, which is the value of Oragenics that is recorded on the company's balance sheet. Investors also form their own opinion of Oragenics' value that differs from its market value or its book value, called intrinsic value, which is Oragenics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oragenics' market value can be influenced by many factors that don't directly affect Oragenics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Oragenics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Oragenics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oragenics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.